From: Comparison of hepatitis B vaccine efficacy in Japanese students: a retrospective study
Vaccine administration route | HBs antibody 2 or 5 months after vaccination | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 months | 5 months | |||||||||||
Total | Men | Women | Total | Men | Women | |||||||
(+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | |
Bimmugen® subcutaneous | 266 | 27 | 175 | 19 | 91 | 8 | 207 | 14 | 8 | 2 | 199 | 12 |
Positive rate | 90.8% | 90.2% | 91.9%* | 93.7% | 80.0% | 94.3%* | ||||||
Heptavax-II® subcutaneous | 161 | 100 | 99 | 76 | 62 | 24 | 87 | 25 | 3 | 2 | 84 | 23 |
Positive rate | 61.7% | 56.6% | 72.1%† | 77.0% | 60.0% | 78.5%† | ||||||
Heptavax-II® intramuscular | 104 | 19 | 76 | 17 | 28 | 2 | 116 | 8 | 3 | 1 | 113 | 7 |
Positive rate | 84.6% | 81.7% | 93.3% ‡ | 93.5% | 75.0% | 94.2%‡ |